Expertise in
13
conditions

Dr. Gottfried E. Konecny

Hematology | Oncology
Office
100 Medical Plz Ste 550, 
Los Angeles, CA 
Offers Telehealth
Expertise in
13
conditions
Office
100 Medical Plz Ste 550, 
Los Angeles, CA 

Overview

Gottfried Konecny is a Hematologist and an Oncologist practicing medicine in Los Angeles, California.

Dr. Konecny is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Ovarian Cancer, Endometrial Cancer, Ovarian Carcinosarcoma, and Sertoli-Leydig Cell Tumor.

He is actively involved in clinical research, co-authoring 131 peer reviewed articles and participating in 9 clinical trials.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in CA

Hospital Affiliations

Ronald Reagan UCLA Medical Center
Santa Monica - UCLA Med Ctr & Orthopaedic Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

Office
100 Medical Plz Ste 550, Los Angeles, CA 90095
Other Locations
Office
100 UCLA Medical Plz Ste 550, Los Angeles, CA 90024

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: August 25, 2026
Intervention Type: Biological
Study Drug: Dostarlimab
Study Phase: Phase 1
A Phase 2, Single Arm Study of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
A Phase 2, Single Arm Study of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Enrollment Status: Completed
Publish Date: January 09, 2026
Intervention Type: Drug
Study Drug: Mirvetuximab Soravtansine
Study Phase: Phase 2
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
Enrollment Status: Completed
Publish Date: August 27, 2025
Intervention Type: Drug
Study Drugs: Mirvetuximab Soravtansine, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin
Study Phase: Phase 3
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody-Drug Conjugate (ADC), in Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody-Drug Conjugate (ADC), in Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers
Enrollment Status: Completed
Publish Date: August 20, 2025
Intervention Type: Drug
Study Drug: STRO-002
Study Phase: Phase 1
A Phase 1B/2 Multicohort Umbrella Study to Evaluate the Safety and Efficacy of Novel Treatments And/Or Combinations of Treatments in Participants With Ovarian Cancer (OPAL)
A Phase 1B/2 Multicohort Umbrella Study to Evaluate the Safety and Efficacy of Novel Treatments And/Or Combinations of Treatments in Participants With Ovarian Cancer (OPAL)
Enrollment Status: Completed
Publish Date: July 15, 2025
Intervention Type: Biological, Drug
Study Drugs: Niraparib, TSR-042 Anti-PD-1 Antibody, Bevacizumab
Study Phase: Phase 2
A Phase II Study of Pembrolizumab Monotherapy in Recurrent Ovarian Cancer of the Immunoreactive Subtype Determined by NanoString Gene Expression Profiling
A Phase II Study of Pembrolizumab Monotherapy in Recurrent Ovarian Cancer of the Immunoreactive Subtype Determined by NanoString Gene Expression Profiling
Enrollment Status: Active_not_recruiting
Publish Date: April 15, 2024
Intervention Type: Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Phase 1 Study Evaluating the Safety and Efficacy of HPV16 E7 T Cell Receptor Engineered T Cells (KITE-439) in HLA-A*02:01+ Subjects With Relapsed/Refractory HPV16+ Cancers
A Phase 1 Study Evaluating the Safety and Efficacy of HPV16 E7 T Cell Receptor Engineered T Cells (KITE-439) in HLA-A*02:01+ Subjects With Relapsed/Refractory HPV16+ Cancers
Enrollment Status: Terminated
Publish Date: December 26, 2023
Intervention Type: Drug
Study Drugs: KITE-439, Cyclophosphamide, Fludarabine
Study Phase: Phase 1
Randomized Phase II Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in HER2/Neu+ Patients With Advance/Recurrent Uterine Serous Papillary Carcinoma
Randomized Phase II Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in HER2/Neu+ Patients With Advance/Recurrent Uterine Serous Papillary Carcinoma
Enrollment Status: Completed
Publish Date: May 17, 2023
Intervention Type: Drug
Study Drugs: Carboplatin/Paclitaxel, Trastuzumab
Study Phase: Phase 2
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma
Enrollment Status: Terminated
Publish Date: June 07, 2022
Intervention Type: Drug
Study Phase: Phase 2
View 8 Less Clinical Trials

131 Total Publications

Real-world clinical outcomes of Trastuzumab Deruxtecan in HER2-expressing ovarian and endometrial Cancer.
Real-world clinical outcomes of Trastuzumab Deruxtecan in HER2-expressing ovarian and endometrial Cancer.
Journal: Gynecologic oncology reports
Published: July 03, 2026
Similar Doctors
Expertise in
11
conditions
Dr. Thomas D. Coates
Hematology | Oncology
Expertise in
11
conditions
Dr. Thomas D. Coates
Hematology | Oncology
Referral may be required

Office

4650 W Sunset Blvd # 54, 
Los Angeles, CA 
 (8.9 miles away)
323-361-4624
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Thomas Coates is a Hematologist and an Oncologist practicing medicine in Los Angeles, California. Dr. Coates is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Hemoglobinopathy, Anemia, Congenital Hemolytic Anemia, Splenectomy, and Bone Marrow Transplant.

Expertise in
31
conditions
Dr. Arun S. Singh
Hematology | Oncology
Expertise in
31
conditions
Dr. Arun S. Singh
Hematology | Oncology
Referral may be required

Sandra Fallon M.D. Inc.

2020 Santa Monica Blvd Ste 580, 
Santa Monica, CA 
 (3.5 miles away)
310-829-5471
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Arun Singh is a Hematologist and an Oncologist practicing medicine in Santa Monica, California. Dr. Singh is highly rated in 31 conditions, according to our data. His clinical expertise encompasses Adult Soft Tissue Sarcoma, Liposarcoma, Ewing Sarcoma, Tissue Biopsy, and Bone Marrow Aspiration.

Expertise in
55
conditions
Dr. Stephen J. Forman
Hematology | Oncology
Expertise in
55
conditions
Dr. Stephen J. Forman
Hematology | Oncology
Referral may be required

City Of Hope Comprehensive Cancer Center-Duarte

1500 Duarte Rd, 
Duarte, CA 
 (27.3 miles away)
888-304-3959
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Stephen Forman is a Hematologist and an Oncologist practicing medicine in Duarte, California. Dr. Forman is highly rated in 55 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Acute Myeloid Leukemia (AML), Graft Versus Host Disease (GvHD), Bone Marrow Transplant, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Gottfried E. Konecny

How do I make an appointment with Dr. Gottfried E. Konecny?

You can book an appointment with Dr. Gottfried E. Konecny by calling their office at 310-794-4955. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Gottfried E. Konecny a top-rated expert for Ovarian Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Gottfried E. Konecny is classified as an Elite expert for Ovarian Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Gottfried E. Konecny specialize in?

While Dr. Gottfried E. Konecny is a Hematology, they have specific expertise in Ovarian Cancer, Endometrial Cancer, and Ovarian Carcinosarcoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Gottfried E. Konecny participate in research or clinical trials?

Yes. Dr. Gottfried E. Konecny has published 131 articles and abstracts on conditions like Ovarian Cancer. You can view a list of Dr. Gottfried E. Konecny's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Gottfried E. Konecny accept my insurance?

Dr. Gottfried E. Konecny accepts most major insurance plans, including Anthem BCBS and Blue Shield of California. We recommend calling the office directly at 310-794-4955 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Konecny's expertise for a condition
ConditionClose
View All 21 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile